161 Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer.
Akram Al-IbraheemAndrew M ScottPublished in: Nuclear medicine and molecular imaging (2023)
Radiotheranostics with 177 Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 ( 161 Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of 161 Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer. Two clinical trials for 161 Tb-PSMA radioligand therapy in prostate cancer are currently underway and will provide valuable insights. This review will shed light on the expanding field of radiotheranostics in prostate cancer, which is not without challenges, and will discuss how the introduction of a new therapeutic option like 161 Tb-PSMA may help to combat these challenges and build on the proven success of 177 Lu-PSMA-based radiotheranostics for the benefit of prostate cancer patients worldwide.
Keyphrases
- prostate cancer
- pet ct
- radical prostatectomy
- pet imaging
- mycobacterium tuberculosis
- clinical trial
- positron emission tomography
- squamous cell carcinoma
- papillary thyroid
- small cell lung cancer
- palliative care
- high resolution
- squamous cell
- stem cells
- systematic review
- randomized controlled trial
- magnetic resonance
- mesenchymal stem cells
- young adults
- climate change
- contrast enhanced
- photodynamic therapy
- high speed
- childhood cancer
- pluripotent stem cells
- atomic force microscopy